Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials.

By K. Ray, S. Seshasai, Shanelle Wijesuriya, Rupa Sivakumaran, S. Nethercott, D. Preiss, S. Erqou, N. Sattar. The Lancet, 2009

1,394 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/d14f632979d2d9b15b9a45ad71adcd94a2aa0119

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

Citations in the corpus

Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. (2013, result): “‘conventional’ control of glucose showed a 17% reduction in myocardial infarction without improvement in stroke or all-cause mortality rates.(73) However, caution is required in the interpretation of these data: the intensive treatment goal of UKPDS was the same as the conventional goal of the more ”
Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes – Mechanisms, Management, and Clinical Considerations (2016, positive): “Intensive glycemic control reduces relative risk of nonfatal myocardial infarction and coronary heart disease events by about 15%, although there is no effect of intensive glycemic control on all-cause mortality in meta-analysis of the multiple randomized clinical trials targeting different intensit”
Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. (2009, positive): “In the ACCORD study, iatrogenic hypoglycemia was associated with excess mortality in both the intensively treated group and the conventionally treated group (20,29).”
Adherence to Therapies in Patients with Type 2 Diabetes (2013, background): “A reduction in non-fatal myocardial infarction and events associated with coronary heart disease can be achieved with intensive glucose-lowering treatment, but involves more medications than conventional treatment [30].”
Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. (2014, background): “selected, mainly younger individuals if it can be accomplished safely and without frequent hypoglycemia.(88,126) Patients with”
Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2002, background): “Although meta-analyses have suggested that intensive glycemic control reduces cardiovascular disease in individuals with type 2 diabetes (47,48), clinical trials have not consistently demonstrated a reduction in macrovascular disease (myocardial infarction or stroke) with intensive therapy aimed at ”
ESH / ESC Guidelines for the management of arterial hypertension (2013, background): “control is likely to reduce non-fatal coronary events and myocardial infarction, as well as nephropathy, but not stroke or all-cause or CV mortality.(667) –669 However, especially in ACCORD, the lower HbA1c target arm was associated with an excess of hypoglycaemic episodes and all-cause mortality.”